233 hasil
Menampilkan 1–20 · 0,28 detik · RSS
healthbook TIMES. Oncology Hematology
Scopus
ISSN 2673-2106 · THE HEALTHBOOK COMPANY LTD. · 233 artikel di indeks
-
Artikel Jurnal
Unmet Medical Needs in Metastatic HER2-Positive Breast Cancer
In human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, taxane-based chemotherapy combined with anti-HER2 antibodies trastuzumab and pertuzumab (THP) has remained the first-line standard of care for more than 13 years, based on data from the phase III CLEOPATRA trial…
-
Artikel Jurnal
Frontline Fixed-Duration Acalabrutinib Plus Venetoclax in Rapidly Progressive _IGHV_-Mutated CLL: A Case Report
# Introduction The phase III AMPLIFY trial established fixed-duration acalabrutinib plus venetoclax as an effective, all-oral, chemotherapy-free frontline therapy for chronic lymphocytic leukemia (CLL). We report the real-world use of this regimen in a patient with rapidly progressive…
-
Artikel Jurnal
Practical Experience with Automated Technologies in Anti-CD19 CAR T-Cell Product Manufacturing
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory hematological malignancies. However, conventional CAR T-cell manufacturing is labor-intensive and costly, faces challenges in scaling production and carries a potential risk of contamination…
-
Artikel Jurnal
Establishing a Geriatric Oncology Service in a Medium-Sized Swiss Hospital: Preliminary Results from the PRO-PAC Registry Study
# Background Older adults account for a disproportionate burden of cancer-related morbidity and mortality; however, they are often underrepresented in clinical trials and may receive suboptimal or non-individualized care. To improve care for this population, we established a geriatric oncology…
-
Artikel Jurnal
Advances in the Treatment of Newly Diagnosed Multiple Myeloma: Current Status and Future Directions
Multiple myeloma (MM) is a hematologic malignancy characterized by frequent relapses and ultimately acquired resistance to therapy across sequential lines of treatment. Nevertheless, treatment options are evolving rapidly, with the introduction of novel agents and immune-based therapies that deepen…
-
Artikel Jurnal
Emerging Role of Oxidized Phospholipids in Tumor Biology
Oxidized phospholipids (OxPLs) are biologically active products of lipid peroxidation that accumulate in the tumor milieu as a consequence of oxidative stress, cell death and metabolic alterations. Recent data suggest that OxPLs are not merely by-products of oxidative injury but active mediators…
-
Artikel Jurnal
Antibody-Drug Conjugate Sequencing in Metastatic Breast Cancer
Antibody-drug conjugates (ADCs) have redefined the therapeutic paradigm of metastatic breast cancer by combining targeted antibody specificity with potent cytotoxic payloads. The regulatory approvals of sacituzumab govitecan (SG), trastuzumab deruxtecan (T-DXd) and datopotamab deruxtecan (Dato-DXd)…
-
Artikel Jurnal
High-Dose Chemotherapy and Stem Cell Transplantation in *ZBTB16::RARA* Acute Promyelocytic Leukemia: A Case Report
A small proportion of patients with acute promyelocytic leukemia (APL) harbor variant chromosomal translocations that lead to fusion of *RARA* to one of several alternative partner genes. The most frequently reported of variant is the t(11;17)(q23;q21), which generates the fusion of the zinc finger…
-
Artikel Jurnal
Hormone Replacement Therapy After Endometrial Cancer: Current Evidence and Treatment Recommendations
Endometrial cancer is the most prevalent gynecologic malignancy in developed countries, with an increasing incidence driven primarily by rising obesity and aging populations. While survival rates are high, particularly for early-stage, low-grade disease, many endometrial cancer survivors experience…
-
Artikel Jurnal
PARP Inhibition as an Effective Therapeutic Strategy in Disseminated TNBC with Extensive CNS Metastases: A Case Report
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by early metastatic spread, limited treatment options and poor prognosis. We describe the case of a 55-year-old woman who presented with disseminated TNBC (lymph nodes, peritoneal and visceral metastasis)…
-
Artikel Jurnal
Bridge the Gap to CAR: Bridging Therapy in CAR T-Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy has fundamentally transformed the treatment paradigm for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). However, implementing this therapy faces logistical and biological hurdles, including the prolonged interval between lymphocyte…
-
Artikel Jurnal
Advances in the Treatment of Higher-Risk MDS: Current Strategies and Emerging Therapies
Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, dysplasia of blood and bone marrow cells, and an elevated risk of progression to acute myeloid leukemia (AML). Patients with higher-risk MDS have a…
-
Artikel Jurnal
Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma
The phase II L-MIND study demonstrated that treatment with tafasitamab in combination with lenalidomide yielded high complete response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients with primary refractory DLBCL relapsing within three months of…
-
Artikel Jurnal
What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024
This mini review explores the evolution of FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy and the current treatment landscape for *FLT3*-mutated acute myeloid leukemia (AML), summarizing insights from the 66th Annual ASH Meeting and Exposition 2024. It highlights the transition from…
-
Artikel Jurnal
Current Advances in the Perioperative Treatment of Muscle-Invasive Bladder Cancer
Muscle-invasive bladder cancer (MIBC) is a highly aggressive disease with a significant risk of recurrence with metastatic disease. Neoadjuvant chemotherapy has been the preferred approach for cisplatin-eligible patients, with regimens such as dose-dense methotrexate, vinblastine, doxorubicin and…
-
Artikel Jurnal
Advances in Prostate Cancer: Insights from ASCO GU 2025
Recent therapeutic advances have significantly improved outcomes for patients with advanced prostate cancer and have transformed the management of the disease. This review highlights some interesting developments in prostate cancer treatment presented at the 2025 American Society of Clinical…